Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Spatially restricted JAG1-Notch signaling in human thymus provides suitable DC developmental niches

  • Martín Gayo, Enrique
  • González García, Sara
  • García León, María J.
  • Murcia Ceballos, Alba
  • Alcain, Juan
  • García Peydró, Marina
  • Allende Martínez, Luis Miguel
  • De Andrés, Belén
  • Gaspar, María L.
  • Toribio, María L.
A key unsolved question regarding the developmental origin of conventional and plasmacytoid dendritic cells (cdcs and pdcs, respectively) resident in the steady-state thymus is whether early thymic progenitors (EtPs) could escape t cell fate constraints imposed normally by a notch-inductive microenvironment and undergo dc development. By modeling dc generation in bulk and clonal cultures, we show here that Jagged1 (JAG1)-mediated notch signaling allows human EtPs to undertake a myeloid transcriptional program, resulting in GAtA2-dependent generation of cd34+ cd123+ progenitors with restricted pdc, cdc, and monocyte potential, whereas delta-like1 signaling down-regulates GAtA2 and impairs myeloid development. Progressive commitment to the dc lineage also occurs intrathymically, as myeloid-primed cd123+ monocyte/dc and common dc progenitors, equivalent to those previously identified in the bone marrow, are resident in the normal human thymus. the identification of a discrete JAG1+ thymic medullary niche enriched for dc-lineage cells expressing notch receptors further validates the human thymus as a dc-poietic organ, which provides selective microenvironments permissive for dc development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Trisomy 8, a cytogenetic abnormality in Myelodysplastic Syndromes, is constitutional or not?

  • Saumell i Tutusaus, Sílvia
  • Solé Ristol, Francesc
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Montoro Gómez, Maria Julia|||0000-0001-9532-7417
  • Valcárcel, David|||0000-0002-8747-078X
  • Pedro, Carme
  • Sanzo, Carmen
  • Luño, Elisa
  • Giménez, Teresa
  • Arnan, Montserrat
  • Pomares, Helena
  • Paz, Raquel de
  • Arrizabalaga, Beatriz
  • Jerez, Andrés|||0000-0002-2079-6638
  • Martínez, Ana B.
  • Sánchez-Castro, Judith
  • Rodríguez-Gambarte, Juan D.
  • Raya, José M.|||0000-0002-7202-5712
  • Ríos, Eduardo
  • Rodríguez-Rivera, María
  • Espinet i Solà, Blanca
  • Florensa Brichs, Maria Lourdes
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). We tried to clarify the incidence of cT8M in myeloid neoplasms, specifically in MDS, and the diagnostic value of isolated +8 in MDS. Twenty-two MDS and 10 other myeloid neoplasms carrying +8 were studied. Trisomy 8 was determined in peripheral blood by conventional cytogenetics (CC) and on granulocytes, CD3+ lymphocytes and oral mucosa cells by fluorescence in situ hybridization (FISH). In peripheral blood CC, +8 was seen in 4/32 patients. By FISH, only one patient with chronic myelomonocytic leukemia showed +8 in all cell samples and was interpreted as a cT8M. In our series +8 was acquired in all MDS. Probably, once discarded cT8M by FISH from CD3+ lymphocytes and non-hematological cells, +8 should be considered with enough evidence to MDS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

  • Margelí, Mireia|||0000-0003-3594-4530
  • Cirauqui, Beatriz|||0000-0002-0136-8056
  • Castellà Fernández, Eva
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Costa, Carla
  • Giménez-Capitán, Ana|||0000-0003-2575-1225
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Ronco, Maria Sanchez
  • Benlloch, Susana
  • Taron, Miquel
  • Rosell, Rafael|||0000-0003-0817-3400
A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA. Tumor biopsies were obtained from 86 breast cancer patients who were candidates for neoadjuvant chemotherapy, treated with four cycles of neoadjuvant fluorouracil, epirubicin and cyclophosphamide. Estrogen receptor (ER), progesterone receptor (PR), HER2, cytokeratin 5/6 and vimentin were examined by tissue microarray. HER2 were also assessed by chromogenic in situ hybridization, and BRCA1 mRNA was analyzed in a subset of 41 patients for whom sufficient tumor tissue was available by real-time quantitative PCR. Median time to progression was 42 months and overall survival was 55 months. In the multivariate analysis for time to progression and overall survival for 41 patients in whom BRCA1 could be assessed, low levels of BRCA1 mRNA, positive PR and negative lymph node involvement predicted a significantly lower risk of relapse, low levels of BRCA1 mRNA and positive PR were the only variables associated with significantly longer survival. We provide evidence for a major role for BRCA1 mRNA expression as a marker of time to progression and overall survival in sporadic breast cancers treated with anthracycline-based chemotherapy. These findings can be useful for customizing chemotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

  • Vázquez, Iria
  • Maicas, Miren|||0000-0003-1404-5552
  • Cervera, José|||0000-0001-8252-1106
  • Agirre, Xabier|||0000-0002-6558-9560
  • Marin-Béjar, Oskar|||0000-0002-6889-6566
  • Marcotegui, Nerea
  • Vicente, Carmen
  • Lahortiga, Idoya
  • Gomez-Benito, Maria
  • Carranza, Claudia
  • Valencia, Ana
  • Brunet, Salut|||0000-0003-0491-1672
  • Lumbreras, Eva
  • Prosper, Felipe|||0000-0001-6115-8790
  • Gomez Casares, Maria Teresa|||0000-0003-0505-5126
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Calasanz, M.J|||0000-0002-0374-3008
  • Sanz, Miguel A..|||0000-0003-1489-1177
  • Sierra Gil, Jorge
  • Odero, María D.
Background: The EVI1 gene (3q26) codes for a zinc finger transcription factor with important roles in both mammalian development and leukemogenesis. Over-expression of EVI1 through either 3q26 rearrangements, MLL fusions, or other unknown mechanisms confers a poor prognosis in acute myeloid leukemia. Design and Methods: We analyzed the prevalence and prognostic impact of EVI1 over-expression in a series of 476 patients with acute myeloid leukemia, and investigated the epigenetic modifications of the EVI1 locus which could be involved in the transcriptional regulation of this gene. Results: Our data provide further evidence that EVI1 over-expression is a poor prognostic marker in acute myeloid leukemia patients less than 65 years old. Moreover, we found that patients with no basal expression of EVI1 had a better prognosis than patients with expression/over-expression (P=0.036). We also showed that cell lines with over-expression of EVI1 had no DNA methylation in the promoter region of the EVI1 locus, and had marks of active histone modifications: H3 and H4 acetylation, and trimethylation of histone H3 lysine 4. Conversely, cell lines with no expression of EVI1 have DNA hypermethylation and are marked by repressive trimethylation of histone H3 lysine 27 at the EVI1 promoter. Conclusions: Our results identify EVI1 over-expression as a poor prognostic marker in a large, independent cohort of acute myeloid leukemia patients less than 65 years old, and show that the total absence of EVI1 expression has a prognostic impact on the outcome of such patients. Furthermore, we demonstrated for the first time that an aberrant epigenetic pattern involving DNA methylation, H3 and H4 acetylation, and trimethylation of histone H3 lysine 4 and histone H3 lysine 27 might play a role in the transcriptional regulation of EVI1 in acute myeloid leukemia. This study opens new avenues for a better understanding of the regulation of EVI1 expression at a transcriptional level.